Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma

Metastatic melanoma is a highly immunogenic tumor with very poor survival rates due to immune system escape-mechanisms. Immune checkpoint inhibitors (ICIs) targeting the cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and the programmed death-1 (PD1) receptors, are being used to impede immune ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Morante, Marta, Pandiella, Atanasio, Crespo, Piero, Herrero, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687808/
https://www.ncbi.nlm.nih.gov/pubmed/36358912
http://dx.doi.org/10.3390/biom12111562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687808/
https://www.ncbi.nlm.nih.gov/pubmed/36358912
http://dx.doi.org/10.3390/biom12111562

Ejemplares similares